First Horizon Advisors’s Maravai LifeSciences MRVI Stock Holding History

First Horizon Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-22	Closed	-$273	–	2463
2023 Q2	$273	Buy	+22	New	+$297	﹤0.01%	2409
2022 Q4	–	Sell	-50	Closed	-$1K	–	2507
2022 Q3	$1K	Sell	50 -88	-64%	-$2.21K	﹤0.01%	2152
2022 Q2	$4K	Buy	138 +31	+29%	+$982	﹤0.01%	1916
2022 Q1	$4K	Buy	+107	New	+$3.59K	﹤0.01%	1341

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

First Horizon Advisors's MRVI Position: Q3 2023 in Review

First Horizon Advisors sold out of Maravai LifeSciences (MRVI) in Q3 2023, closing a stake of 22 shares — an estimated $273 sold.

First Horizon Advisors first reported a position in MRVI in Q1 2022 and held it in 4 quarters. The position peaked at $4K in Q2 2022. 204 funds tracked by Wall St. Rank hold MRVI as of Q3 2023.

First Horizon Advisors reported no remaining Maravai LifeSciences position as of Q3 2023 after selling out during the quarter.
First Horizon Advisors sold 22 Maravai LifeSciences shares in Q3 2023, an estimated $273.
First Horizon Advisors first reported a position in Maravai LifeSciences in Q1 2022 and held it in 4 quarters.
First Horizon Advisors's Maravai LifeSciences position peaked at $4K in Q2 2022.
204 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2023.

Based on First Horizon Advisors's 13F filing for Q3 2023, filed 27 Oct 2023.